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We thank Berry el al(1) for their letter regarding our recent study(2), suggesting 
we used incomplete data, as we did not include those studies reporting median 
index microvascular resistance (IMR). However, in our study, we had pre-
specified the inclusion of those studies reporting mean and not median IMR. 
Although different methods are available for converting median values to mean 
ones, they are based on various assumptions, and each method derives 
different mean values and standard deviations (SD). The latest study(3) 
referred to by Berry et al was not identified on Pubmed or Embase at the time 
our manuscript was being prepared. Even if we were able to access the raw 
data from that study, their IMR values were non-normally distributed and using 
mean values instead, would have been statistically flawed, and not reflective of 
the actual IMR in each group. Besides, the excluded studies also showed a 
significant difference in IMR values between those with and without MVO 
and/or intramycardial hemorrhage (IMH), and the overall conclusion of our 
study would have been similar. To illustrate this, we have now used the formula 
interquartile range/1.35 as suggested by the Cochrane Handbook(4) to derive 
the SD of these 3 studies mentioned in their letter(1), and have updated our 
analysis.  The IMR in the MVO/IMH group (n=290) was significantly higher than 
the no MVO/IMH group (n=297): 41U (99%CI 37-46) versus 22U (99%CI 19-
25)(P<0.001), and the heterogeneity among the studies increased from 0% to 
28%. We have not provided the SD for each group, as it is highly likely to be 
inaccurate. 
We commend the Berry et al for their tremendous work in this field and we 
would welcome any future collaborative work to advance the field. Large 
variability in IMR still exists, and there is a need for standardizing IMR 
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measurement across centers. Even from a single-center study, the sensitivity 
and specificity of IMR>27U to detect MVO with IMH was only at 66% and 67%, 
respectively, and an IMR<27U (rather than >27U as stated in their 
manuscript(3)) had a negative predictive value of 74%. As it stands, it appears 
from their data(3), that if a cardioprotective strategy is administered prior to or 
immediately after reperfusion, then 50% ST-resolution by eletrocardiography at 
60 minutes would perform equally well to IMR to track a putative treatment 
effect, and cardiovascular magnetic resonance remains the gold standard. 
However, we agree with them that if the aim is to identify high-risk patients 
immediately post-PPCI and target them with further adjuvant therapies, aiming 
to restore microvascular perfusion, then IMR would be valuable. 
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